| Data indicate that LASP1 may have an oncogenic function and that it might be regulated by miR-1, miR-133a, and miR-218, which may function as tumor suppressive miRNAs in bladder cancer (BC). | bladder, |
| GSTP1 may have an oncogenic function and may be regulated by miR-133alpha, a tumor suppressive miRNA in HNSCC. | HNSC, |
| MSN was regulated by tumor suppressive miR-133a and contributed to HNSCC oncogenesis. | HNSC, |
| this analysis data of novel tumor-suppressive miR-133a-mediated cancer pathways could provide new insights into the potential mechanisms of HNSCC oncogenesis. | HNSC, |
| CD47 expression is a novel prognostic marker in esophageal squamous cell carcinoma that is directly inhibited by the miR-133a tumor suppressor. | esophageal, |
| findings showed miR-133a was frequently downregulated in colorectal cancer tissues and colon cancer lines; restoration of miR-133a in colon cancer cells resulted in G0-G1 cell-cycle arrest and suppressed cancer cell growth; miR-133a serves as a potential tumor suppressor upstream of p53 in colorectal cancer and may sensitize cells to therapeutics | colorectal, |
| the tumor suppressor role of miR-133a in lung cancer | lung, |
| miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. | pancreatic, |
| Suggest that miR-133a is downregulated in gastric cancer and functions as a tumor suppressor in vitro and in vivo partly by repressing IGF1R. | gastric, |
| The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer | endometrial, |
| These findings suggest that miR-133a may act as a tumor suppressor and inhibited survival of hepatocellular carcinoma cells by targeting IGF-1R | liver, |
| miR-133b/a-3p acts as a tumor suppressor in gastric cancer by directly targeting Mcl-1 and Bcl-xL. | gastric, |
| Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma | osteosarcoma, |
| miR-133 function as tumour suppressor in glioma and inhibit cell proliferation and invasioned by directly targeting FOXC1 | glioma, |
| Our results demonstrate that miR-133a plays a pivotal role in colorectal cancer by inhibiting cell proliferation, invasion, and migration by targeting oncogenic eukaryotic translation initiation factor 4A1, which acts as a tumor suppressor and may provide a new potential therapeutic target in colorectal cancer | colorectal, |
| Study finds miR-133a expression significantly downregulated in breast cancer (BC) tissues and cell lines and, significantly associated with advanced clinical stage, lymph node metastasis, as well as shorter survival time of BC patients. Also, the study demonstrates that miR-133a acts as a tumor suppressor in breast cancer partly at least via targeting LASP1. | breast, |
| Study indicated that miR-133a might act as a tumor suppressor and be a valuable independent prognostic and diagnostic biomarker for non-small cell lung cancer (NSCLC), and NSCLC patients with high expression of miR-133 might have a better prognosis.[meta-analysis] | lung, |
| MiR-133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-?/Smad3 signaling pathway | lung, |
| The combined expression of FSCN1 and MMP14 is associated with a poor prognosis, and miR-133a, which regulates their mRNAs, can serve as a strong tumour suppressor of ESCC. | None |